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disease entities?Immunoglobulin A (IgA) nephropathy (IgAN) is one of the
most common causes of primary glomerulonephritis (GN), and
shows diverse clinical presentations, leading to progressive renal
failure in some patients [1]. The etiology of IgAN is considered to
be multifactorial [2]. The genetic factors may inﬂuence disease
susceptibility and the likelihood of the disease progressing to
end-stage renal disease. Evidence for a genetic contribution has
come from the observation that some families are affected in an
apparently autosomal dominant fashion, although this is not
common [3–5]. Furthermore, ethnicity seems to inﬂuence sus-
ceptibility to the disease and impacts upon disease progression.
The prevalence of IgAN varies among racial groups, as is most
common among Asians and American Indians, intermediate in
Hispanics and Caucasians, and rare in African and American
blacks. In addition to the genetic determinants of disease
susceptibility, there are genetic associations with the tendency
for IgAN to progress. The analyses of the genetic polymorphisms
of several cytokines and chemokines have beenwidely performed
for the elucidation of genetic determinants of IgAN regarding
susceptibility and progression.
Thin basement membrane nephropathy (TBMN) is one of the
most common causes of persistent hematuria in children and
adults, the othermain etiologies being Alport’s syndrome and IgAN
[6,7]. Besides hematuria, patients with TBMN usually have mini-
mal proteinuria, normal renal function, and uniformly thinned
glomerular basement membranes (GBMs), as determined by
electron microscopy [8]. In some patients, microscopic hematuria
is intermittent and may not be detected until adulthood. Episodic
gross hematuria, often in association with upper respiratory tract
infections, which is typical for IgAN, is not unusual. TBMN was
originally known to have a benign clinical course associated with
family history. Overt proteinuria and hypertension are unusual in
TBMN. Other glomerular disorders, such as IgAN and focal or
global glomerulosclerosis, may occur concurrently with TBMN,
altering the usual natural clinical course and histopathology of the
condition [6]. Voskarides et al. reported that in cases of combined
focal segmental glomerulosclerosis on biopsy, the prognosis was
not good in a signiﬁcant proportion of patients [9]. TBMN mainly
manifests as an inherited disorder with autosomal dominant
transmission affecting approximately one-half of successive gen-
erations. Approximately two-thirds of patients with TBMN have at
least one other relative with hematuria. The remaining one-third132/$ - see front matter & 2012. The Korean Society of Nephrology. P
nse (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dx.doi.org/10.1016/j.krcp.2012.10.001of patients may have de novo mutations or the nonpenetrance in
other members of the family. About half of TBMN is caused by the
mutation of COL4A3/COL4A4 genes of type IV collagen, and the
remainders occur sporadically [7].
IgAN is diagnosed by the predominant deposition of IgA in the
mesangial region, therefore it cannot be made without a renal
biopsy, nomatter how suggestive the clinical presentationmay be.
Serum IgA is often increased, and there may be IgA in cutaneous
blood vessels. Serum complement concentrations are normal.
These ﬁndings, however, are not reliable enough to support the
diagnosis without a renal biopsy. Mesangial IgA occurs in other
conditions, such as lupus nephritis, alcoholic liver disease, and IgA
monoclonal gammopathy, which can usually be differentiated on
clinical, serologic, and histologic criteria. None of the light micro-
scopic features are of themselves diagnostic of IgAN.
The diagnosis of TBMN is also conﬁrmed by a renal biopsy
and genetic analyses [8]. The GBM does not reveal any
structural abnormalities, but it is characteristically thinned,
sometimes having only approximately half of the thickness
expected in a normal kidney. Endothelial cells and podocyte
foot processes maintain normal morphological features.
The characteristic manifestation of TBMN is persistent hema-
turia of glomerular origin; therefore, it is important to distin-
guish this benign disease from other, superimposing causes of
glomerular hematuria, such as IgAN, postinfectious GN,
mesangiocapillary GN, and lupus nephritis. Whereas IgAN
and TBMN may be difﬁcult to distinguish on clinical grounds
alone, other forms of GN are frequently associated with
additional clinical features that rarely are seen in TBMN, such
as proteinuria, hypertension, renal impairment, and systemic
symptoms. Genetic analysis is useful for discrimination
between Alport syndrome and TBMN. Segregation of the
disease with the COL4A5 locus and sequencing of all of the
exon regions can reveal over 80% of the mutations in X-linked
Alport syndrome. Sequencing of the COL4A3 and COL4A4 genes
is also required for the diagnosis of familial forms of TBMN [7].
In this issue of Kidney Research and Clinical Practice, Jung et al.
report the results of their investigation into the effects of gene
polymorphisms on the development of IgAN and TBMN of several
cytokines including interleukin-18 (IL-18), transforming growth
factor-b (TGF-b), and vascular endothelial growth factor (VEGF)
in Korean patients [10]. Furthermore, they tried to discriminateublished by Elsevier. This is an open access article under the CC BY-NC-
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cytokine gene polymorphisms without a renal biopsy. In the
study, the frequencies of the IL-18-607CC genotype and the VEGF
405GG genotype were signiﬁcantly increased in IgAN patients
compared with the control group, whereas no signiﬁcant differ-
ences in genotype frequency were observed between TBMN and
control groups. There were no signiﬁcant differences, however, in
genotype and allele frequencies between IgAN and TBMN groups.
The authors concluded that their study did not show any
statistically signiﬁcant differences in the six selected gene poly-
morphisms of IL-18, TGF-b, and VEGF between IgAN and TBMN,
and additional extensive studies are required to clarify the
potential role of gene polymorphism in discriminating between
IgAN and TBMN without a renal biopsy.
Cytokines are polypeptide regulatory hormones that are
produced during the activation and effector phases of innate
and speciﬁc immunity, and constitute a cellular signaling system.
They serve to mediate and regulate immune and inﬂammatory
responses, and have many functional roles in GN [11]. Chemo-
kines cover a large family of structurally homologous cytokines
that share an ability to stimulate leukocyte motility and directed
movement, and act as inﬂammatory mediators. In the kidney,
several chemokines are present in the glomeruli or tubulointer-
sitium, and they are considered to have active roles in renal
damage. Considering the characteristics of cytokines and chemo-
kines, such as pleiotropism, redundancy, production by multiple
diverse cell types, and inﬂuences on the action of other mole-
cules, an evaluation of integrated working networks of cytokines
and chemokines is required for the elucidation of their roles in
the pathogenetic mechanisms of glomerulonephritides. Until
now, lots of studies dealt with these subjects by studying
different cytokines, however, genetic diversity including gene
polymorphisms of various cytokines has not been determined as
a deﬁnite initiator or modulator of primary GN.
The differentiation between IgAN and TBMN is quite impor-
tant because of their different clinical courses and approaches to
treatment [1,12]. Contrary to the benign nature of TBMN, a
substantial proportion of IgAN patients progresses to end-stage
renal disease. As I mentioned above, we should consider the
complexity and diversity of cytokines and chemokines in the
understanding of their roles in the development or progression of
primary GN. Ideally we should ﬁgure out the integrated working
system of cytokines. Unfortunately, the networks of cytokines
and chemokines are still evolving. We cannot therefore consider
the genetic analyses of several cytokines as a deﬁnite diagnostic
tool for the differentiation of renal diseases at present.
The pathogenetic mechanisms of IgAN and TBMN are quite
different. Whereas TBMN is considered a genetic disorder
involving GBM type IV collagen, the pathogenesis of IgAN is
still hypothetical and associated with multiple factors, includ-
ing immunological abnormalities producing abnormal IgA.
Considering all the aspects of pathogenetic mechanisms, the
theoretical concepts of the authors, that is, that differential
diagnosis of IgAN and TBMN can be achieved with the genetic
analyses of limited number of cytokines, seems to be imprac-
tical [10]. The classical diagnostic methods including a renal
biopsy are deﬁnitely needed to discriminate between these
two common diseases causing persistent hematuria.
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